Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mohamed Ismail Abdul Aziz
Observed name:
Aziz, Mohamed Ismail Abdul
Institution:
Ministry of Health
Observed institution:
Ministry of Health
ORCID:
0000-0003-3606-7672
Observed ORCID:
0000-0003-3606-7672
OpenAlex ID:
A5007239888
Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis
2018
·
Mohamed Ismail Abdul Aziz
, Ling Eng Tan
, et al.
·
International Journal of COPD
·
60
PDF
Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction
2017
·
Lin Liang
, David Bin-Chia Wu
, et al.
·
Journal of Medical Economics
·
38
PDF
Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer
2020
·
Lee Cheng Phua
, Soo Chin Lee
, et al.
·
BMC Health Services Research
·
36
PDF
Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore’s healthcare system perspective
2020
·
Boon Piang Cher
, Kar Yee Gan
, et al.
·
Journal of Medical Economics
·
33
PDF
Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective
2018
·
Ping-Tee Tan
, Mohamed Ismail Abdul Aziz
, et al.
·
BMC Cancer
·
29
PDF
Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer
2020
·
Mohamed Ismail Abdul Aziz
, Ling Eng Tan
, et al.
·
Journal of Medical Economics
·
28
PDF
Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore
2020
·
Mohamed Ismail Abdul Aziz
, Wayne Yong Xiang Foo
, et al.
·
Journal of Medical Economics
·
26
PDF
Assessing the cost-effectiveness of mepolizumab as add-on therapy to standard of care for severe eosinophilic asthma in Singapore
2020
·
Ling Eng Tan
, Wan Hui Gloria Tan
, et al.
·
Journal of Asthma
·
22
PDF
Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore
2019
·
Sil-ling Pruis
, Mohamed Ismail Abdul Aziz
, et al.
·
International Journal of Technology Assessment in Health Care
·
18
PDF
Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore
2021
·
Lee Cheng Phua
, Horace C.W. Choi
, et al.
·
Vaccine
·
17
Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer
2021
·
Li-Jen Cheng
, Grace Wong
, et al.
·
Expert Review of Pharmacoeconomics & Outcomes Research
·
15
Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore
2021
·
Li-Jen Cheng
, Lydia Loke
, et al.
·
Expert Review of Pharmacoeconomics & Outcomes Research
·
15
Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore
2020
·
Sil-ling Pruis
, Yunjoo Karris Jeon
, et al.
·
Journal of Medical Economics
·
15
Cost‐effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore
2020
·
Lydia Loke
, Soo‐Chin Lee
, et al.
·
Cancer Reports
·
11
PDF
Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma
2021
·
Xin Yi Wong
, Wee Joo Chng
, et al.
·
Expert Review of Pharmacoeconomics & Outcomes Research
·
10
Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore
2023
·
Boon Piang Cher
, Sharon Goh
, et al.
·
Expert Review of Pharmacoeconomics & Outcomes Research
·
9
Cost-effectiveness analysis of trastuzumab emtansine for second-line treatment of HER2+ advanced breast cancer in Singapore
2025
·
Wei Han Melvin Wong
, Raymond Ng
, et al.
·
Expert Review of Pharmacoeconomics & Outcomes Research
·
1
Reply: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction
2018
·
Lin Liang
, David Bin-Chia Wu
, et al.
·
Journal of Medical Economics
·
1
PDF
Cost-effectiveness of ruxolitinib in Singapore for patients with chronic graft-versus-host disease
2025
·
Naren Kumar Surendra
, Jiamin Ong
, et al.
·
Expert Review of Pharmacoeconomics & Outcomes Research
PP61 Cost-Effectiveness Analysis Of Trastuzumab Deruxtecan Versus Chemotherapy For Previously Treated HER2-Positive Gastric Cancer In Singapore
2023
·
Ivan Koh
, Ling Eng Tan
, et al.
·
International Journal of Technology Assessment in Health Care
PDF
Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore
2023
·
Cher, Boon Piang
, Goh, Sharon
, et al.
·
Figshare
Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer
2020
·
Aziz, Mohamed Ismail Abdul
, Tan, Ling Eng
, et al.
·
Figshare
OP116 Cost-Effectiveness Of Sacubitril/Valsartan In Heart Failure
2017
·
Liang Lin
, Mohamed Ismail Abdul Aziz
, et al.
·
International Journal of Technology Assessment in Health Care
PDF
Show more works
View as search
Works count:
23
Citation count:
384
H-index:
13
I10-index:
15
Year
Topic
Type